Summary & Overview
HCPCS J3285: Injection, treprostinil, 1 mg
HCPCS Level II code J3285 denotes the injection of treprostinil, billed per 1 mg, a prostacyclin analog used in treating pulmonary arterial hypertension and other vascular conditions. Nationally, this drug code matters because it represents a high-cost, specialty parenteral therapy administered across outpatient infusion centers, hospital outpatient departments, and ambulatory settings, impacting payer coverage policies and site-of-service cost differentials.
Key payers addressed in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines what readers will learn about coding and billing considerations for J3285, payer coverage patterns, common sites of service where the drug is administered, and how this code is recorded on medical claims. The summary highlights available benchmarks and policy context where present; where input data is not provided, the text notes that specific details are not available.
Readers will find a concise clinical context for treprostinil injections, typical billing scenarios, and a roadmap to the sections that follow covering modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service-line considerations. Data not available in the input is identified as such in the detailed sections.
Billing Code Overview
HCPCS Level II code J3285 represents an injection of treprostinil, billed per 1 mg. This code captures administration of the prostacyclin analogue treprostinil, used in the management of pulmonary arterial hypertension and related vascular conditions.
-
Service type: Drug injection / parenteral pharmacologic therapy
-
Typical site of service: Outpatient infusion center, hospital outpatient department, ambulatory clinic, or physician office
Clinical & Coding Specifications
Clinical Context
A 55-year-old patient with pulmonary arterial hypertension (PAH) presents to an outpatient specialty infusion clinic for administration of a parenteral prostacyclin analog. The treating pulmonary hypertension specialist orders J3285 (injection, treprostinil, 1 mg) to titrate and maintain therapy. The clinical workflow includes medication verification by pharmacy, preparation of the treprostinil dose under aseptic technique, patient identity verification, assessment of vital signs and symptoms (including right-sided heart failure signs, oxygenation, and site integrity), and administration via the patient’s established subcutaneous infusion pump or intravenous central venous catheter. Post-injection monitoring for adverse effects (flushing, headache, hypotension, infusion site pain, bleeding, or catheter complications) is performed for an appropriate observation period. Documentation includes dose amount (mg), route (subcutaneous or intravenous), lot number, time, clinician performing the injection, and any immediate adverse reactions. Billing uses J3285 per milligram of treprostinil supplied; units billed correspond to milligrams administered or dispensed per payer rules.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Specialty inherent to the service | Use when the provider is the usual specialty who performs the injection (e.g., pulmonary hypertension specialist) and payer requires specialty indicator. |